Clinical Trial

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2019-12-09; most recent amendment 2026-03-17.
Status change: Not Yet Recruiting → Recruiting 2020-07-10
Trial Details
NCT Number NCT04192344
Lead Sponsor Abbisko Therapeutics Co, Ltd
Conditions Neoplasms, Tenosynovial Giant Cell Tumor
Enrollment 276 participants
Start Date 2020-01-20
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-19